Protection of infant mice against pertussis, tuberculosis and influenza by co-administration of nasal pertussis vaccine candidate BPZE1 and BCG

IF 4.1 2区综合性期刊 Q1 MULTIDISCIPLINARY SCIENCES

iScience Pub Date : 2025-06-07 DOI:10.1016/j.isci.2025.112839

Carine Rouanet , Anne-Sophie Debrie , Stephane Cauchi , Nathalie Mielcarek

{"title":"Protection of infant mice against pertussis, tuberculosis and influenza by co-administration of nasal pertussis vaccine candidate BPZE1 and BCG","authors":"Carine Rouanet , Anne-Sophie Debrie , Stephane Cauchi , Nathalie Mielcarek","doi":"10.1016/j.isci.2025.112839","DOIUrl":null,"url":null,"abstract":"<div><div>Protecting neonates at risk of serious pertussis disease or death represents a global emergency. BPZE1 is the most advanced, next-generation pertussis vaccine undergoing clinical evaluation in children and adults. We investigated the feasibility of co-administering BPZE1 and Bacillus Calmette-Guerin (BCG), the most widely used tuberculosis vaccine worldwide. We showed that BPZE1 can be co-administered with BCG without altering its immunogenicity and protective efficacy against <em>B. pertussis</em> in infant mice. Conversely, BCG immunogenicity and protective efficacy against <em>M. tuberculosis</em> are not affected by BPZE1. Both vaccines induce off-target protection against heterologous infections. In this study, we showed that BPZE1 and BCG alone or in combination induced high levels of protection against influenza challenge in infant mice. In contrast to BCG, the off-target properties of BPZE1 were independent of the age of vaccination. Vaccination with BPZE1 might be considered at the same time as BCG, facilitating its effective implementation in the childhood immunization schedule.</div></div>","PeriodicalId":342,"journal":{"name":"iScience","volume":"28 7","pages":"Article 112839"},"PeriodicalIF":4.1000,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"iScience","FirstCategoryId":"103","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2589004225011009","RegionNum":2,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Protecting neonates at risk of serious pertussis disease or death represents a global emergency. BPZE1 is the most advanced, next-generation pertussis vaccine undergoing clinical evaluation in children and adults. We investigated the feasibility of co-administering BPZE1 and Bacillus Calmette-Guerin (BCG), the most widely used tuberculosis vaccine worldwide. We showed that BPZE1 can be co-administered with BCG without altering its immunogenicity and protective efficacy against B. pertussis in infant mice. Conversely, BCG immunogenicity and protective efficacy against M. tuberculosis are not affected by BPZE1. Both vaccines induce off-target protection against heterologous infections. In this study, we showed that BPZE1 and BCG alone or in combination induced high levels of protection against influenza challenge in infant mice. In contrast to BCG, the off-target properties of BPZE1 were independent of the age of vaccination. Vaccination with BPZE1 might be considered at the same time as BCG, facilitating its effective implementation in the childhood immunization schedule.

Abstract Image

查看原文本刊更多论文

鼻百日咳候选疫苗BPZE1和卡介苗联合接种对幼鼠百日咳、肺结核和流感的保护作用

保护面临严重百日咳疾病或死亡风险的新生儿是一项全球紧急事项。BPZE1是正在进行儿童和成人临床评估的最先进的下一代百日咳疫苗。我们研究了BPZE1与世界上最广泛使用的结核病疫苗卡介苗（Bacillus Calmette-Guerin， BCG）联合接种的可行性。我们发现BPZE1可以与卡介苗共同施用，而不会改变其对幼鼠百日咳的免疫原性和保护作用。相反，BPZE1不影响卡介苗的免疫原性和对结核分枝杆菌的保护作用。这两种疫苗都能诱导对异源感染的脱靶保护。在这项研究中，我们发现BPZE1和BCG单独或联合在幼鼠中诱导了高水平的对流感攻击的保护。与卡介苗相比，BPZE1的脱靶特性与接种年龄无关。可考虑与卡介苗同时接种BPZE1，以促进其在儿童免疫计划中的有效实施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

iScience Multidisciplinary-Multidisciplinary

CiteScore

7.20

自引率

1.70%

发文量

1972

审稿时长

6 weeks

期刊介绍： Science has many big remaining questions. To address them, we will need to work collaboratively and across disciplines. The goal of iScience is to help fuel that type of interdisciplinary thinking. iScience is a new open-access journal from Cell Press that provides a platform for original research in the life, physical, and earth sciences. The primary criterion for publication in iScience is a significant contribution to a relevant field combined with robust results and underlying methodology. The advances appearing in iScience include both fundamental and applied investigations across this interdisciplinary range of topic areas. To support transparency in scientific investigation, we are happy to consider replication studies and papers that describe negative results. We know you want your work to be published quickly and to be widely visible within your community and beyond. With the strong international reputation of Cell Press behind it, publication in iScience will help your work garner the attention and recognition it merits. Like all Cell Press journals, iScience prioritizes rapid publication. Our editorial team pays special attention to high-quality author service and to efficient, clear-cut decisions based on the information available within the manuscript. iScience taps into the expertise across Cell Press journals and selected partners to inform our editorial decisions and help publish your science in a timely and seamless way.